SS
FULC icon

SBI Securities’s Fulcrum Therapeutics FULC Stock Holding History

SBI Securities’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Hold
4
– – ﹤0.01% 3886
2026
Q1 		$31 Hold
4
– – ﹤0.01% 3672
2025
Q4 		$45 Sell
4
-24
-86% -$244 ﹤0.01% 3593
2025
Q3 		$258 Buy
28
+2
+8% +$14 ﹤0.01% 3233
2025
Q2 		$179 Hold
26
– – ﹤0.01% 3352
2025
Q1 		$75 Hold
26
– – ﹤0.01% 3538
2024
Q4 		$122 Buy
+26
New +$96 ﹤0.01% 3399

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SBI Securities's FULC Position: Q2 2026 in Review

SBI Securities held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 4 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #3886.

SBI Securities first reported a position in FULC in Q4 2024 and has held it in 7 quarters since. The position peaked at $258 in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • SBI Securities held 4 shares of Fulcrum Therapeutics worth $15 as of Q2 2026.
  • SBI Securities left its Fulcrum Therapeutics share count unchanged in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3886 holding.
  • SBI Securities first reported a position in Fulcrum Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Fulcrum Therapeutics position peaked at $258 in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.